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Results
MacLennan et al. (2008)
• Double-blind randomized controlled trial (RCT), 48 subjects,     
5-15 years old, 24 males and 24 females
• Performed in Australia, participants recruited primarily from 
school newsletters
• Riboflavin 200mg daily vs. placebo for 12 weeks
• No significant decrease in migraine frequency
• No significant decrease in migraine severity
• No significant decrease in migraine duration
Condo et al. (2009)
• Retrospective observational study, 41 participants 8-18  years old, 
16 males and 25 females
• Performed in Italy at an outpatient specialty university clinic
• Riboflavin 200mg daily vs. 400mg daily for 3, 4, or 6 months
• Significant decrease in migraine frequency
• Significant decrease in migraine severity
• Increased response to symptomatic treatment
• Males under the age of 12 were most likely to receive benefit
Bruijn et al. (2010)
• Double-blind, cross-over RCT, 42 participants, 6-13 years old,  
24 males and 18 females
• Performed in the Netherlands, recruited by referral
• Riboflavin 50mg daily vs. placebo for 16 weeks
• No significant decrease in migraine frequency
• No significant decrease in migraine severity
• No significant decrease in migraine duration
Discussion
Limitations of Studies
• Terms “pediatric,” “children,” & “adolescents” not clearly defined
• All studies included patients with other headache types
MacLennan et al. (2008)
• Relatively small sample did not meet proposed sample of 56
• Strict inclusion & exclusion criteria excluded 44 patients and may 
not represent average migraine patient
• High placebo response rate, 66%
Condo et al. (2009)
• No placebo control group, cannot measure placebo response rate
• Recommended immediate acute treatment during riboflavin phase 
• No blinding of patients or researchers
• Included resistant migraine with failure of previous therapy
• Relatively small sample size
Bruijn et al. (2010)
• Riboflavin 50mg used despite negative results of MacLennan et 
al. (2008) at higher dose
• No upper limit of headaches per month
• Comparison between groups limited to last 4 weeks of treatment
• Relatively small sample size
GRADE
• This tool provides a GRADE of the quality of evidence which 
explains how likely future research is to change the effect or 
confidence in the effect.
Introduction
•Migraine headache is a common condition among children 
and the prevalence increases into adolescence.
• Migraine headaches are typically unilateral, pulsating, 
moderate to severe in intensity, made worse by physical 
activity and can be associated with nausea and vomiting, 
photophobia, and phonophobia.
•“For a clinical problem so prevalent in children and 
adolescents, there is a disappointing lack of evidence from 
controlled, randomized, and masked trials” (Lewis et al., 
2004, p. 2215).
•Several acute treatments exist for pediatric migraine but
there are currently no medications with an FDA approved 
indication for migraine prophylaxis in children.
•The goal of preventive treatment is to reduce the frequency, 
severity, and duration of migraine episodes, to improve 
responsiveness to acute treatment, and to improve 
functioning and reduce disability.
•A number of supplements have been used for migraine 
prophylaxis, including riboflavin (vitamin B2), which has 
been shown in multiple trials to be effective for migraine 
prophylaxis in adults.
Purpose
• To perform a systematic review of the literature on the use 
of riboflavin for migraine prophylaxis in the pediatric 
population including children and adolescents.
• The quality of evidence will be evaluated using the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) tool developed by the GRADE 
Working Group.
Method
•MEDLINE, CINAHL, Evidence Based Medicine Reviews 
Multifile, Web of Science, and PubMed, were accessed 
through the Pacific University Library.
• Keyword search terms “migraine” and “riboflavin” 
searched in combination returned 242 articles.
•Search limits:  human studies, articles published in 
English, published from 2000-2011; 139 articles
•Studies of adult patients, duplicates, descriptive 
reviews, and letters to the editor were excluded.
•Three studies pertaining to the use of riboflavin in children 
and adolescents for migraine prophylaxis are analyzed in 
this review.
Conclusion
• There is currently low quality evidence supporting the use of riboflavin as migraine prophylaxis in children and 
adolescents and only a weak recommendation can be made for its use. 
•Future research should:
•Utilize high quality RCTs with large sample size in cross-over or parallel group design
•Test riboflavin 200mg, 300mg, 400mg daily, or higher dose, alone or in combination
•Consider investigating the use of a weight based dose in the pediatric population
•Investigate potential difference between diagnostic criteria of migraine  used clinically and in research
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Table 1: GRADE Table
GRADE (Continued)
• A GRADE of high, moderate, low, or very low is 
assigned to the evidence
• High Quality:  Further research is very unlikely to 
change our confidence in the estimate of effect
• Moderate Quality:  Further research is likely to have 
an important impact on our confidence in the estimate 
of effect and may change the estimate
• Low Quality:  Further research is very likely to have 
an important impact on our confidence in the estimate 
of effect and is likely to change the estimate
• Very Low Quality:  Any estimate of effect is very 
uncertain
Migraine Frequency
• Starting GRADE High for RCTs, Low for Obs. study
• RCTs downgraded for study quality & consistency
• End GRADE Low
Migraine Severity
• Starting GRADE High for RCTs, Low for Obs. study
• RCTs downgraded for study quality & consistency
• End GRADE Low
Migraine Duration
• Starting GRADE High for RCTs
• RCTs downgraded for study quality & consistency
• End GRADE Moderate
• Overall GRADE is Low which suggests further research 
is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to 
change the estimate.
